<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00416351</url>
  </required_header>
  <id_info>
    <org_study_id>06-065</org_study_id>
    <secondary_id>P30CA008748</secondary_id>
    <secondary_id>MSKCC-06065</secondary_id>
    <nct_id>NCT00416351</nct_id>
  </id_info>
  <brief_title>Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment</brief_title>
  <official_title>A Phase I/II Study of Clofarabine in Patients With Relapsed T-Cell and NK-Cell Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as clofarabine, work in different ways to stop&#xD;
      the growth of cancer cells, either by killing the cells or by stopping them from dividing.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of clofarabine and&#xD;
      to see how well it works in treating patients with T-cell or natural killer-cell lymphoma&#xD;
      that has relapsed or not responded to previous treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of clofarabine in patients with relapsed or&#xD;
           refractory T-cell or natural killer-cell lymphoma.&#xD;
&#xD;
        -  Determine the toxicity of this drug in these patients.&#xD;
&#xD;
        -  Determine, preliminarily, the efficacy of this drug, in terms of response rate, in these&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: This is a phase I, non-randomized, dose-escalation study followed by an open-label,&#xD;
      phase II study.&#xD;
&#xD;
        -  Phase I: Patients receive clofarabine IV over 1 hour once daily on days 1-3. Treatment&#xD;
           repeats every 21 days for up to 2 courses in the absence of disease progression or&#xD;
           unacceptable toxicity. Patients achieving stable disease or partial response (PR) or&#xD;
           complete response (CR) may receive 2 additional courses of treatment. Patients with PR&#xD;
           or CR after completing 4 courses of therapy may receive 2 additional courses.&#xD;
&#xD;
      Cohorts of 1-6 patients receive escalating doses of clofarabine until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
        -  Phase II: Patients receive clofarabine as in phase I at the MTD determined in phase I.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 27, 2006</start_date>
  <completion_date type="Actual">March 1, 2021</completion_date>
  <primary_completion_date type="Actual">March 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (Phase I)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate as defined by complete remission, complete remission unconfirmed, partial remission, positron emission tomography (PET)-negative partial remission, stable disease, and progressive disease (Phase II)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity as defined by NCI Common Terminology Criteria for Adverse Events v 3.0</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Small Intestine Cancer</condition>
  <arm_group>
    <arm_group_label>Clofarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive intravenous clofarabine once daily for three consecutive days. Doses of clofarabine will start at 4 mg/m2/day and will be escalated to higher dose levels.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clofarabine</intervention_name>
    <arm_group_label>Clofarabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed T-cell or natural killer (NK)-cell lymphoma, including any of&#xD;
             the following subtypes:&#xD;
&#xD;
               -  Blastic NK-cell lymphoma&#xD;
&#xD;
               -  T/NK-cell lymphoma/leukemia&#xD;
&#xD;
               -  Adult T-cell lymphoma/leukemia&#xD;
&#xD;
               -  T-cell prolymphocytic leukemia&#xD;
&#xD;
               -  T-lymphoblastic lymphoma&#xD;
&#xD;
               -  Peripheral T-cell lymphoma, not otherwise specified&#xD;
&#xD;
               -  Angioimmunoblastic T-cell lymphoma&#xD;
&#xD;
               -  Anaplastic large cell lymphoma&#xD;
&#xD;
               -  Transformed mycosis fungoides&#xD;
&#xD;
               -  Subcutaneous panniculitis-like T-cell lymphoma&#xD;
&#xD;
               -  Nasal T/NK-cell lymphoma&#xD;
&#xD;
               -  Enteropathy-type T-cell lymphoma&#xD;
&#xD;
               -  Hepatosplenic gamma/delta T-cell lymphoma&#xD;
&#xD;
          -  Relapsed or refractory disease, meeting both of the following criteria:&#xD;
&#xD;
               -  Must have been treated with prior cytotoxic chemotherapy and/or monoclonal&#xD;
                  antibody therapy&#xD;
&#xD;
               -  No standard curative treatment exists&#xD;
&#xD;
                    -  Allogeneic bone marrow transplantation is not considered standard curative&#xD;
                       treatment&#xD;
&#xD;
          -  Evaluable disease (Phase I)&#xD;
&#xD;
          -  Measurable disease, defined as any nodal site or mass lesion ≥ 1.5 cm in longest&#xD;
             transverse diameter on physical exam or CT scan OR a measurable extranodal site &gt; 1 cm&#xD;
             (Phase II)&#xD;
&#xD;
               -  Patients with evaluable blood- or marrow-based disease are eligible&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm³ (Phase I)&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 500/mm³ (Phase II)&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³ (Phase I)&#xD;
&#xD;
          -  Platelet count ≥ 50,000/mm³ (Phase II)&#xD;
&#xD;
          -  Creatinine &lt; 2.0 mg/dL*&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 times upper limit of normal (ULN)*&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times ULN*&#xD;
&#xD;
          -  No active infection requiring antibiotics&#xD;
&#xD;
          -  No New York Heart Association class III or IV congestive heart failure&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
          -  No other active malignancy requiring therapy&#xD;
&#xD;
          -  No other serious or life-threatening condition deemed unacceptable by the principal&#xD;
             investigator&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception NOTE: *Unless due to lymphoma and&#xD;
             patients are entering to the phase II portion of the study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior therapy, including any of the following:&#xD;
&#xD;
               -  Interferon&#xD;
&#xD;
               -  Antibody therapy&#xD;
&#xD;
               -  Retinoids&#xD;
&#xD;
               -  Other non-chemotherapeutic treatment&#xD;
&#xD;
          -  Concurrent stable-dose corticosteroids allowed&#xD;
&#xD;
          -  No colony-stimulating factor therapy during the first course of study therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven M. Horwitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James P. Wilmot Cancer Center at University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 27, 2006</study_first_submitted>
  <study_first_submitted_qc>December 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2006</study_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>prolymphocytic leukemia</keyword>
  <keyword>childhood nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>small intestine lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clofarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

